A trend toward lower mortality among patients who received remdesivir (7.1%) than among those who received placebo (11.9%) was also observed, but the difference did not reach statistical significance.
1
—
—
A trend toward lower mortality among patients who received remdesivir (7.1%) than among those who received placebo (11.9%) was also observed, but the difference did not reach statistical significance.